anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 271,621-271,650
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

271,621-271,650 of 303,780

filter-aware
14
The chart uses a broken axis to represent the significantly larger patient population for HER2 overexpressing cancers compared to mutations.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
15
The chart uses a logarithmic scale for selectivity. The right side provides a qualitative critique of competitor molecules.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
16
Includes a list of abbreviations at the bottom.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
17
Imara | Mergers and Acquisitions Presentation Deck | 45 slidesImara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
18
Includes a stylized chemical structure graphic.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
20
The slide uses a split-screen layout to contrast clinical challenges with the rationale for treatment switching.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
22
Includes clinical trial data and resistance mutation analysis.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
24
The slide uses a custom table structure to show competitive positioning of ELVN-001 against existing TKI generations.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
25
The slide outlines the strategic positioning of a drug candidate (ELVN-001) by contrasting its desired profile against current standards of care.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
26
Includes structural biology diagrams of BCR-ABL protein domains and a table comparing binding conformations.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
27
The table highlights key differentiators such as lower BCRP substrate status and improved plasma protein binding for ELVN-001.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
28
Includes both a competitive cellular phosphorylation table and a specific kinase selectivity table for ELVN-001.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
29
The slide uses a scatter plot for efficacy correlation and a bar chart for safety margin comparison.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
30
The slide uses a process-oriented layout to show the progression of clinical trials.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
31
Features a stylized chemical structure graphic.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
32
Uses a before-after framing to contrast market limitations with product solution.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
33
The chart uses a broken axis to represent the significantly larger patient population for HER2 overexpressing cancers compared to the initial focus areas.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
34
The slide contrasts established therapies with investigational ones, emphasizing the lack of selective TKIs and the resulting toxicity issues.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
35
The slide highlights a gap in the market for a selective, irreversible TKI for brain metastases.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
36
Includes a list of abbreviations at the bottom.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
37
The table uses a heatmap-style color coding (green for favorable, red for unfavorable) to visualize potency differences.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
38
The table highlights ELVN-002's superior selectivity (sparing EGFR) and better pharmacokinetic properties compared to competitors.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
39
The slide uses a logarithmic scale for selectivity. The right side provides a qualitative critique of competitor molecules.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
40
Data shows ELVN-002 efficacy and safety profile compared to Tucatinib and Poziotinib.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
41
The slide compares efficacy (BLI signal) and PK (concentration over time) to demonstrate superior potency of ELVN-002 at lower exposures.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
42
Includes references to Li et al. Cancer Disc 2020 and Abraham et al. J Clin Oncol 2019.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
43
Includes a line chart showing concentration over time and a table summarizing safety margin folds at different doses.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
44
Uses a process-oriented layout to show progression of clinical trials.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
45
The slide uses a stylized chemical structure as a background element.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
01
Slide 1
Innovative Eyewear | Investor Presentation Deck | 21 slidesInnovative Eyewear | Investor Presentation Deck | 21 slides · Innovative Eyewear
Pitch deck Investor relations 1 hit